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Abstract
Background: A current challenge of coping with bacterial infection is that bacterial pathogens are becoming less
susceptible to or more tolerant of commonly used antibiotics. It is urgent to work out a practical solution to
combat the multidrug resistant bacterial pathogens.
Findings: Oxidative stress-acclimatized bacteria thrive in rifampicin by generating antibiotic-detoxifying nitric oxide
(NO), which can be repressed by artesunate or an inhibitor of nitric oxide synthase (NOS). Suppressed bacterial
proliferation correlates with mitigated NO production upon the combined treatment of bacteria by artesunate with
antibiotics. Detection of the heme-artesunate conjugate and accordingly declined activities of heme-harbouring
bacterial NOS and catalase indicates that artesunate renders bacteria susceptible to antibiotics by alkylating the
prosthetic heme group of hemo-enzymes.
Conclusions: By compromising NO-mediated protection from antibiotics and triggering harmful hydrogen
peroxide burst, artesunate may serve as a promising antibiotic synergist for killing the multidrug resistant
pathogenic bacteria.
Findings
Artesunate is a semi-synthetic soluble derivative of arte-
misinin, a plant sesquiterpene endoperoxide lactone
with pleiotropic functions of anti-malaria, anti-tumour
and anti-inflammation [1]. Here, we report that artesu-
nate can also exert an accelerated anti-bacterial activity
in combination with antibiotics. Initially, we found that
artesunate mitigated the oxidative stress-induced gen-
eration of nitric oxide (NO) from the Gram-positive
bacterium, Bacillus licheniformis.Ag r a d u a li n c r e a s eo f
nitrate/nitrite, the oxidation product of NO, was
detected in the bacterial culture standing without agita-
tion either at room temperature (the hypoxia group) or
in a 4°C refrigerator (the hypoxia + cold group)
although no significant difference was observed between
the hypoxia + cold group and the hypoxia group (Figure
1). In similar, it has been demonstrated that NO is not
consumed and accumulates in the microenvironment of
human tissue at lower oxygen concentrations [2]. It is
also manifested from Figure 1 that oxidative stress-trig-
gered NO generation was repressed by either artesunate
or a specific inhibitor of nitric oxide synthase (NOS),
NG-monomethyl-L-arginine monoacetate (L-NMMA),
indicating that artesunate may represent a novel NOS
inhibitor that acts in an unknown manner.
Knowing that bacterial NO can detoxify antibiotics
through direct or indirect mechanisms [3], we tested
whether NO that was triggered by acclimatization to
hypoxia confers B. licheniformis tolerance to the antibio-
tic rifampicin. Consequently, when bacteria propagated
to a logarithmic phase in the absence of rifampicin,
acclimatized bacteria started to proliferate at a higher
rate than non-acclimatized bacteria in the presence of
rifampicin (Figure 2a). Similarly, acclimatized bacteria
also showed somewhat accelerated proliferation in the
presence of either cefotaxime (Figure 2b) or ampicillin
(Figure 2c).
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teria, artesunate was anticipated to reverse NO-mediated
protection of bacteria from antibiotics. Indeed, artesu-
nate in combination with rifampicin led to more strin-
gent growth inhibition of B. licheniformis than
rifampicin alone. As illustrated in Figure 3a, much
slower growth of bacteria was monitored in artesunate
+ rifampicin than in rifampicin, hence addressing that
artesunate potentiates rifampicin perhaps by attenuating
NO production from bacteria. In the present study, we
observed that enhanced NO burst occurred in bacteria
that were exposed to rifampicin, whereas less NO was
measured in bacteria that were co-treated by artesunate
with rifampicin (Figure 3b).
In the NOS-free Gram-negative bacterium, Escherichia
coli, a complex compassing nitrite reductase, flavohemoglo-
bin and a NO-sensing regulator is harnessed to form NO
[4]. Indeed, we detected the generation of NO in E. coli,
either in the presence or absence of cefotaxime, but no cor-
relation of bacterial proliferation with NO production was
established (Figure 4a and 4b). From the extremely low
level of NO in E. coli,w ei n f e r r e dt h a ts u c hat r a c ea m o u n t
o fN Om i g h ti n s u f f i c i e n tt os e n s i t i z ec e f o t a x i m e .
The non-pathogenic Bacillus subtilis and pathogenic
Bacillus anthracis as well as many other Gram-positive
bacteria generate NO by their own NOS that associates
w i t hap r o s t h e t i ch e m eg r o u pf o rt h er e d u c t i o no ff e r r i c
heme [Fe
3+] to ferrous heme [Fe
2+] [5]. Given that heme
alkylation by artemisinin has been verified by identifying
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Figure 1 Production of NO from B. licheniformis upon
acclimatization to oxidative stress and suppression of
oxidative stress-inducible NO as incubation of B. licheniformis
with artesunate or a NOS inhibitor. ART: artesunate; L-NMMA: NG-
monomethyl-L-arginine monoacetate. Double asterisks (**) represent
very significant difference from the control (P < 0.01); Double wells
(##) represent very significant difference from the hypoxia + cold
group (P < 0.01).
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Figure 2 Inducible NO-mediated protection of B. licheniformis
from antibiotics. (a) Propagation of acclimatized or non-
acclimatized B. licheniformis in the presence of rifampicin. (b)
Propagation of acclimatized or non-acclimatized B. licheniformis in
the presence of cefotaxime. (c) Propagation of acclimatized or
non-acclimatized B. licheniformis in the presence of ampicillin. Ac:
acclimatization to hypoxia; NonAc: non-acclimatization to hypoxia.
Rif: rifampicin; Cef: cefotaxime; Amp: ampicillin.
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Figure 3 Bacterial propagation and NO generation in the presence of antibiotics or artesunate + antibiotics for B. licheniformis.( a )
Propagation of B. licheniformis in the presence of rifampicin or artesunate + rifampicin. (b) Generation of NO from B. licheniformis in the
presence of rifampicin or artesunate + rifampicin. Rif: rifampicin; ART: artesunate.
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Figure 4 Bacterial propagation and NO generation in the presence of antibiotics or artesunate + antibiotics for E. coli. (a) Propagation
of E. coli in the presence of cefotaxime or artesunate + cefotaxime. (b) Generation of NO from E.coli in the presence of cefotaxime or artesunate
+ cefotaxime. Cef: cefotaxime; ART: artesunate.
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Page 4 of 7the heme-artemisinin adduct in malaria-infected mice [6],
and the interaction between heme and artesunate has
been also recognised by monitoring the dynamic shift of
one peak specific to heme and another peak unique to the
heme-artesunate conjugate in tumour cells [7], we
assumed that artesunate would also bind to the heme
group of bacterial NOS and hence prohibit the inter-con-
version of Fe
3+ with Fe
2+ within the hemoprotein. Indeed,
A415 that reflects the absorbance of heme and A476 that
represents the absorbance of the heme-artesunate conju-
gate reached high values after the bacterial culture was
supplemented with artesunate for 3 h (Figure 5), suggest-
ing that the A415 peak was likely resulted from the increase
of NOS, while the A476 peak was probably derived from
the conjugation of heme with artesunate. Nevertheless, the
increase of NOS needs the overexpression of a corre-
sponding gene that encodes NOS in B. licheniformis,
whether NOS gene is inducible by artesunate-bound inac-
tivation of NOS awaits further elucidation.
Until recently, there has no documented evidence
regarding the impact of artesunate on bacterial catalase.
Considering that catalase is also a heme-harbouring
enzyme among Bacillus [8], it can be deduced that a
similar mechanism exists in B. licheniformis,b yw h i c h
artesunate binds to the prosthetic heme group of cata-
lase and abrogates the conversion of hydrogen peroxide.
Therefore, we further measured catalase activity after
incubating bacteria with rifampicin or rifampicin + arte-
sunate. The results showed that enzyme activity was
considerably reduced once artesunate was included in
the culture (Figure 6). In other observations, NO acti-
vates catalase in bacteria by diminishing the rate of
cystine reduction to cysteine, which drives the Fenton
reaction and simultaneously inhibits catalase [9]. Due to
catalase inhibition, hydroxyl radicals that were derived
from excess hydrogen peroxide exhibit the extreme toxi-
city to bacterial DNA through base modifications and
strand breaks [10]. It can be concluded that artesunate
facilitates the action of antibiotics against bacteria by
synchronously inactivating NOS and catalase. Interest-
ingly, artesunate also covalently binds to hemoproteins
of tumour cells and potentiates the cytotoxicity of 5-
fluorouracil in vitro and in vivo [11], implying that a
common mechanism exists to interfere with the fate of
bacterial and tumour cells. However, inhibition of a bac-
terial multidrug efflux pump system should represent an
alternative manner of artesunate in sensitizing antibio-
tics [12].
A current challenge of coping with bacterial infection
is that bacterial pathogens are becoming less susceptible
to or more tolerant of commonly used antibiotics. For
example, globally endemic tuberculosis caused by multi-
drug resistant strains of Mycobacterium tuberculosis
remains a formidable threat to human health. Although
the development of more potent antibiotics may prohi-
bit the lethal pathogens from worldwide transmission, it
has proved to be costly, time-consuming and technically
difficult [13]. Otherwise, if an antibiotic synergist like
artesunate can benefit to fight against the antibiotic
resistant bacteria, it will minimise the dosage of antibio-
tics in antibacterial therapy and diminish the heavy inci-
dence and rapid transmission of multidrug resistant
bacterial pathogens.
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Figure 5 Time-course monitoring of the heme-artesunate
conjugate in B. licheniformis incubated with artesunate. ART:
artesunate. A415 represents the absorbance of heme at the
wavelength of 415 nm; A476 represents the absorbance of the
heme-artesunate conjugate at the wavelength of 476 nm.
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Figure 6 Determination of catalase activity in B. licheniformis
upon exposure to rifampicin or artesunate + rifampicin. ART:
artesunate; Rif: rifampicin. A single asterisk (*) represents
significant difference of the artesunate + rifampicin group from the
rifampicin group (P < 0.05); Double asterisks (**) represent very
significant difference of the artesunate + rifampicin group from the
rifampicin group (P < 0.01).
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Bacterial culture and NO content estimation
A single colony of B. licheniformis BL20386 or E. coli
DH5a was inoculated in LB broth and cultured over-
night at 37°C. A 1% aliquot of pre-cultured bacteria was
inoculated in LB broth and cultured at 37°C until absor-
bance at 600 nm (A600) to 0.6. For oxidative stress accli-
matization, triangle bottles with the bacterial culture
were placed without agitation for 3 d at room tempera-
ture (the hypoxia group) or in a 4°C refrigerator (the
hypoxia + cold group). For antibiotic exposure, a 1% ali-
quot of the overnight bacterial culture was inoculated in
LB broth supplementing with different concentrations of
rifampicin, cefotaxime, or ampicillin. For inhibitor treat-
ment, a 1% aliquot of the overnight bacterial culture
was inoculated in LB broth supplementing with 60 μg/
ml artesunate or 1 mM NG-monomethyl-L-arginine
monoacetate (L-NMMA). On each day, 1 ml of the bac-
terial culture was taken out for estimation of NO con-
tent using a commercially available kit and according to
the manufacturer’s instruction. The content of NO is
represented by the amount of nitrate (NO3
-)/nitrite
(NO2
-). For plotting a standard curve of nitrate/nitrite, 1
M NaNO3 was dissolved to a series of dilutions (1, 2, 5,
10, 20, 30, 40, 60 μM) by LB broth for measurement of
A540, from which a regression equation and a determi-
nant coefficient were calculated.
Bacterial growth assay
For monitoring the growth rate of oxidative stress-accli-
matized bacteria, a 1% aliquot of the bacterial culture
standing at room temperature for 3 d or that without oxi-
dative stress treatment was inoculated in LB broth supple-
menting with rifampicin and cultured at 37°C with
agitation. After cultured for 3, 6, 9 and 12 h, 1 ml of the
bacterial culture was taken out and diluted with 9 ml of
fresh LB broth to measure A600 for plotting the growth
rate curve. For assaying the bacterial growth rate following
treatment by rifampicin or artesunate + rifampicin, a 1%
aliquot of the overnight bacterial culture was inoculated in
LB broth supplementing with 60 μg/ml artesunate and dif-
ferent concentration of rifampicin, and cultured at 37°C.
After cultured for 3, 6, 9, 12 and 24 h, 1 ml of the bacterial
culture was diluted with 9 ml of fresh LB broth to measure
A600 for plotting the growth rate curve.
Detection of heme and heme-artesunate conjugate
A 1% overnight culture of B. licheniformis BL20386 was
inoculated in LB broth supplementing with 60 μg/ml
artesunate and cultured at 37°C for 2 d. The triangle
bottle with a pre-culture was first placed at ambient
temperature for 1 d and subsequently at a 4°C refrigera-
tor for 1 d. After supplementing with fresh LB broth
and 60 μg/ml artesunate, the bacterial strain was con-
tinuously cultured overnight at 37°C. The culture was
taken out on 3, 6 and 9 h for collecting cells by centri-
fugation and lysing them through repeated cycles of fro-
zen-thaw, and finally the lysate was applied to measure
A415 and A476.
Determination of catalase activity
A 1% overnight culture of B. licheniformis BL20386 was
inoculated in LB broth supplementing with 60 μg/ml
artesunate in the treatment group or without artesunate
in the control group, and cultured at 37°C for 2 d. The
triangle bottle with a pre-culture was first placed at
ambient temperature for 1 d and subsequently at a 4°C
refrigerator for 1 d. After supplementing with fresh LB
broth containing 60 μg/ml artesunate or 60 μg/ml arte-
sunate + different concentrations of rifampicin, the bac-
terial strain was continuously cultured overnight at 37°
C. The culture was taken out from each group on 9, 12
and 24 h for measurement of A405 using a commercially
available kit. The activity of catalase (U/ml) was calcu-
lated according the formula of (A405 control group -A 405
treatment group) × 271 × 1/6.
Acknowledgements
This work was supported by Natural Science Foundation of Guangdong
China (No. 9145624536-4000003) and Scientific Development Project of
Guangdong China (No. 2007B031404008).
Author details
1Tropical Medicine Institute, Guangzhou University of Chinese Medicine,
Guangzhou, China.
2Artemisinin Research Centre, Guangzhou University of
Chinese Medicine, Guangzhou, China.
3Simplex Biotechnologies, LLC, Clinton,
NJ08809, USA.
Authors’ contributions
NX, PW and XQY were responsible for bacterial culture and drug evaluation.
LXZ and XXG carried out the spectrophotometric assay. PZZ performed the
statistical analysis. QPZ designed and coordinated the experiment. FQ
helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 February 2011 Accepted: 30 June 2011
Published: 30 June 2011
References
1. Krishna S, Bustamante L, Haynes RK, Staines HM: Artemisinins: their
growing importance in medicine. Trends Pharmacol Sci 2008, 29:520-527.
2. Taylor CT, Moncada S: Nitric oxide, cytochrome C oxidase, and the
cellular response to hypoxia. Arterioscler Thromb Vasc Biol 2010,
30:643-647.
3. Gusarov I, Shatalin K, Starodubtseva M, Nudler E: Endogenous nitric oxide
protects bacteria against a wide spectrum of antibiotics. Science 2009,
325:1380-1384.
4. Corker H, Poole RK: Nitric oxide formation by Escherichia coli. J Biol Chem
2003, 278:31584-31592.
5. Gusarov I, Starodubtseva M, Wang ZQ, McQuade L, Lippard SJ, Stuehr DJ,
Nudler E: Bacterial nitric-oxide synthases operate without a dedicated
redox partner. J Biol Chem 2008, 283:13140-13147.
Zeng et al. BMC Research Notes 2011, 4:223
http://www.biomedcentral.com/1756-0500/4/223
Page 6 of 76. Robert A, Benoit-Vical F, Claparols C, Meunier B: The antimalarial drug
artemisinin alkylates heme in infected mice. Proc Natl Acad Sci USA 2005,
102:13676-13680.
7. Zhang SM, Gerhard GS: Heme mediates cytotoxicity from artemisinin and
serves as a general anti-proliferation target. PLoS ONE 2009, 4:e7472.
8. Bol DK, Yasbin RE: Analysis of the dual regulatory mechanisms
controlling expression of the vegetative catalase gene of Bacillus subtilis.
J Bacteriol 1994, 176:6744-6748.
9. Gusarov I, Nudler E: NO-mediated cytoprotection: instant adaptation to
oxidative stress in bacteria. Proc Natl Acad Sci USA 2005, 102:13855-13860.
10. Woodmansee AN, Imlay JA: Reduced flavins promote oxidative DNA
damage in non-respiring Escherichia coli by delivering electrons to
intracellular free iron. J Biol Chem 2002, 277:34055-34066.
11. Zeng QP, Zhang PZ: Artesunate mitigates proliferation of tumor cells by
alkylating heme-harboring nitric oxide synthase. Nitric Oxide 2011,
24:110-112.
12. Li B, Yao Q, Pan XC, Wang N, Zhang R, Li J, Ding G, Liu X, Wu C, Ran D,
Zheng J, Zhou H: Artesunate enhances the antibacterial effect of β-
lactam antibiotics against Escherichia coli by increasing antibiotic
accumulation via inhibition of the multidrug efflux pump system AcrAB-
TolC. J Antimicrob Chemother 2011, 66:769-777.
13. Patel BA, Crane B: When it comes to antibiotics, bacteria show some NO-
how. J Mol Cell Biol 2010, 2:234-236.
doi:10.1186/1756-0500-4-223
Cite this article as: Zeng et al.: Artesunate potentiates antibiotics by
inactivating heme-harbouring bacterial nitric oxide synthase and
catalase. BMC Research Notes 2011 4:223.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zeng et al. BMC Research Notes 2011, 4:223
http://www.biomedcentral.com/1756-0500/4/223
Page 7 of 7